Find more information in our portfolio of scientific documents
Library
Contact our Team
Host Cell Protein analysis with Mass Spectrometry The power of impurity identification 2018 Poster

Developing and producing recombinant biopharmaceuticals in mammalian cells requires unambiguous monitoring of HCPs impurities. Immunoassays are still the method of choice for release testing, for which it is recommended to demonstrate the suitability of antisera in a QM-regulated environment to meet regulatory demands. However, peptide analysis by MS has been proven to be a powerful tool by providing complementary data for HCP characterization.

Development of a quantitative mass spectrometry-based multi-attribute method (MAM) 2018 Poster

In the context of the production and development of biosimilar or new biological agents, it is necessary to analyze multiple samples of different process stages. Thereby differences to corresponding originator products as well as variances between the different samples must be viewed critically.
We present an optimization of MAM in IgG1 biosimilar development using Thermo Scientific Q Exactive HF-X instrumentation and the software solution (Protein Metrics Inc.) for fast processing of product quality attributes (PQAs) like post-translational modification levels, terminal variants and…

In Vivo CQA Mapping/Biotransformation Analysis — Opportunities in De-risking and Advancing Biologic Drug Development Scientific Paper

As a key element of biologic development today, precise characterizations of a drug candidate’s structures, post translational modifications (PTM’s) and determinations of its Critical Quality Attributes (CQA’s) are essential in defining, optimizing and controlling development programs from early candidate design through bioproduction scale-up, CMC package development, clinical trials, BLA submission and post-launch commercialization.

Mass Spectrometry - A powerful tool box for Host Cell Protein analysis 2017 Poster

Developing and producing recombinant biopharmaceuticals in mammalian cells requires unambiguous monitoring of HCPs impurities. Immunoassays are still the method of choice for release testing, for which it is recommended to demonstrate the suitability of antisera in a QM-regulated environment to meet regulatory demands. However, peptide analysis by MS has been proven to be a powerful tool by providing complementary data for HCP characterization.

Domain specific N-glycan profiling of a Fc-fusion antibody 2016 Poster

The development and production of recombinant biopharmaceuticals and their biosimilars
is a challenging field due to their structural complexity. While demonstrating batch to batch
comparability is a demanding analytical task, demonstrating biosimilarity is even more
challenging as it is already performed during early development with limited knowledge of
the structural features of the biosimilar candidate and limited molecule specific method
experience. Additionally analytical methods in biosimilar development need to be applied
for different aspects…

Mass Spectrometry: A powerful tool for Host Cell Protein analysis Poster

Developing and producing recombinant biopharmaceuticals in mammalian cells requires unambiguous monitoring of HCPs impurities. Immunoassays are still the method of choice
for release testing, for which it is recommended to demonstrate the suitability of antisera in a
QM-regulated environment to meet regulatory demands. However, peptide analysis by MS has been proven to be a powerful tool by providing complementary data for HCP characterization.

In Vivo Attribute Quantitation and PK Modeling mAbs 2016 Scientific Paper

A thorough understanding of drug metabolism and disposition can aid in the assessment of efficacy and safety.
However, analytical methods used in pharmacokinetics (PK) studies of protein therapeutics are usually based on
ELISA, and therefore can provide a limited perspective on the quality of the drug in concentration
measurements. Individual post-translational modifications (PTMs) of protein therapeutics are rarely considered
for PK analysis, partly because it is technically difficult to recover and quantify individual protein variants from
biological…

In Vivo Assessments of Quality Attributes mAbs 2016 Scientific Paper

Characterization of biopharmaceutical proteins and assessment and understanding of the critical
quality attributes (CQAs) is a significant part of biopharmaceutical product development and is routinely
performed in vitro. In contrast, systematic analysis of the quality attributes in vivo is not as widespread,
although metabolism and clearance of multiple variants of therapeutic proteins administered to nonhuman
primates and human subjects may have a different impact on safety, efficacy and exposure. The
major hurdles of such studies are usually sample…

Analytical support in cell line- and process development for achieving biosimilarity 2015 Poster

The development of biosimilars is a challenging field due to the need of achieving highest similarity to a structural highly complex molecule. The establishment and development of a high
productive and robust production process represents a challenging and critical path prior to the biosimilar comparability demonstration. When implementing a process for the synthesis of
new biological entities (NBE) or biosimilars, variations in the protein structure or post-translational modifications can occur. A subset of qualified and robust analytical methods are
required to monitor…

Challenges of Demonstrating Biosimilarity 2015 Poster

The development and production of recombinant biopharmaceuticals and their biosimilars
is a challenging field due to their structural complexity. While demonstrating batch to batch
comparability is a demanding analytical task, demonstrating biosimilarity is even more
challenging as it is already performed during early development with limited knowledge of
the structural features of the biosimilar candidate and limited molecule specific method
experience. Additionally analytical methods in biosimilar development need to be applied
for different aspects…

I agree to be contacted and have read and accepted the TERMS OF USE and PRIVACY POLICY

Newsletter

See here our latest newsletter. The company is constantly informing in E-Mail about latest technology developments,
typical applications, as well as strategic approaches in biotherapeutic development.

SIGN UP HERE

SERVICES

Protagen Protein Services (PPS) is a world leading CRO and recognized expert for analytical services in protein science regarding characterization, method development, validation and routine testing of antibodies, proteins, vaccines and other formates of biopharmaceuticals. Our sites are equipped with modern, state-of-the-art equipment for the analytical characterization of biopharmaceuticals regarding structure, purity, chemical modification, aggregation, particle formation, thermal stability e.g.. We offer service modules for analytcal support from research to approval regarding:

  • Developability
  • Clone Selection & Process Development
  • Extendend Characterization & Comparability
  • Stability & Release

READ MORE